[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Top Cited Papers
- 11 February 2021
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 397 (10276), 797-804
- https://doi.org/10.1016/s0140-6736(21)00237-3
Abstract
No abstract availableKeywords
Funding Information
- Endocyte
- Movember Foundation
- Prostate Cancer Foundation of Australia
This publication has 18 references indexed in Scilit:
- Accuracy of Dose Calibrators for 68Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial AssessmentJournal of Nuclear Medicine, 2018
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Journal of Clinical Oncology, 2016
- Response and Tolerability of a Single Dose of177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective AnalysisJournal of Nuclear Medicine, 2016
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617Journal of Nuclear Medicine, 2016
- WIDEN: A tool for medical image management in multicenter clinical trialsClinical Trials, 2014
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerThe New England Journal of Medicine, 2004